Stereotaxis to Initiate First-in-Human Trial to Support CE Mark Application of MAGiC Catheter
Stereotaxis’ MAGiC catheter is a robotically-navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures. The catheter’s CE Mark submission was made in
“We look forward to advancing the MAGiC catheter into clinical use and are working expeditiously to ensure the technology becomes available to patients and the electrophysiology community as soon as possible,” said
“Stereotaxis continues to experience demand for its Genesis robotic system, and reiterates its expectation of double-digit revenue growth in 2023. Our strong financial position allows us to advance a robust innovation strategy through commercialization without the need for additional financing. This innovation strategy, including a highly-accessible robot with proprietary interventional catheters for use in electrophysiology and broadly across endovascular interventions, serves as the foundational product ecosystem to transform endovascular surgery with robotics.”
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the
Chairman and Chief Executive Officer
Chief Financial Officer
Source: Stereotaxis, Inc.